Showing results (161-170 of 626) with videos related to
Sort By:
Pageof 63
Clinical Genitourinary Cancer|October 10, 2009
Drug management of prostate cancer: prevalence and consequences of renal insufficiencyVincent Launay-Vacher, Jorge Ayllon, Nicolas Janus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Persistence of medical change at implementation of clinical guidelines on medical practice: a controlled study in a cancer networkIsabelle Ray-Coquard, Thierry Philip, Guy de Laroche, et al.Lung|October 23, 2008
Lung cancer and renal insufficiency: prevalence and anticancer drug issuesVincent Launay-Vacher, Reza Etessami, Nicolas Janus, et al.Virchows Archiv : an International Journal of Pathology|April 25, 2023
CREB fusion-associated epithelioid mesenchymal neoplasms of the female adnexa: three cases documenting a novel location of an emerging entity and further highlighting an ambiguous misleading immunophenotypeAlexis Trecourt, Nicolas Macagno, Carine Ngo, et al.Cancers|September 10, 2021
TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian CancerJulie Lecuelle, Romain Boidot, Hugo Mananet, et al.Annales De Pathologie|August 1, 2025
[Optimal tissue quantity for molecular ancillary studies in multicenter clinical trials in gynecological oncology: Experience of the GINECO pathologists' group]Alexis Trecourt, Guillaume Bataillon, Isabelle Treilleux, et al.Gynecologic Oncology|January 26, 2016
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabaseJacek P Grabowski, Philipp Harter, Florian Heitz, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.European Journal of Cancer (Oxford, England : 1990)|May 13, 2026
COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort studyPierre-Etienne Heudel, Virginie Avrillon, Benedicte Mastroianni, et al.Pageof 63